Next Article in Journal
Cancer Vaccines: Research and Applications
Next Article in Special Issue
Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies
Previous Article in Journal
In Vivo Assessment of VCAM-1 Expression by SPECT/CT Imaging in Mice Models of Human Triple Negative Breast Cancer
Previous Article in Special Issue
AP-1 Transcription Factors as Regulators of Immune Responses in Cancer
Review

Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors

Department of Oncology-Pathology, Karolinska Institutet, S-17164 Stockholm, Sweden
*
Authors to whom correspondence should be addressed.
Received: 29 May 2019 / Revised: 15 July 2019 / Accepted: 18 July 2019 / Published: 23 July 2019
(This article belongs to the Special Issue Signaling Pathways and Immune Checkpoint Regulation in Cancer)
The immune system plays a crucial role to prevent local growth and dissemination of cancer. Therapies based on activating the immune system can result in beneficial responses in patients with metastatic disease. Treatment with antibodies targeting the immunological checkpoint axis PD-1 / PD-L1 can result in the induction of anti-tumor T cell activation leading to meaningful long-lasting clinical responses. Still, many patients acquire resistance or develop dose-limiting toxicities to these therapies. Analysis of tumors from patients who progress on anti-PD-1 treatment reveal defective interferon-signaling and antigen presentation, resulting in immune escape from T cell-mediated attack. Natural killer (NK) cells are innate lymphocytes that can kill tumor cells without prior sensitization to antigens and can be activated to kill tumor cells that have an impaired antigen processing and presentation machinery. Thus, NK cells may serve as useful effectors against tumor cells that have become resistant to classical immune checkpoint therapy. Various approaches to activate NK cells are being increasingly explored in clinical trials against cancer. While clinical benefit has been demonstrated in patients with acute myeloid leukemia receiving haploidentical NK cells, responses in patients with solid tumors are so far less encouraging. Several hurdles need to be overcome to provide meaningful clinical responses in patients with solid tumors. Here we review the recent developments to augment NK cell responses against solid tumors with regards to cytokine therapy, adoptive infusion of NK cells, NK cell engagers, and NK cell immune checkpoints. View Full-Text
Keywords: natural killer cells; immune checkpoint; tumor microenvironment natural killer cells; immune checkpoint; tumor microenvironment
Show Figures

Figure 1

MDPI and ACS Style

Chen, Z.; Yang, Y.; Liu, L.L.; Lundqvist, A. Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors. Cancers 2019, 11, 1040. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers11071040

AMA Style

Chen Z, Yang Y, Liu LL, Lundqvist A. Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors. Cancers. 2019; 11(7):1040. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers11071040

Chicago/Turabian Style

Chen, Ziqing, Ying Yang, Lisa L. Liu, and Andreas Lundqvist. 2019. "Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors" Cancers 11, no. 7: 1040. https://0-doi-org.brum.beds.ac.uk/10.3390/cancers11071040

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop